Module 3: Type 2 Diabetes

Diabetes Screening/Diagnosis
Kathleen Dungan, MD, MPH

  • Prevention & Delay of T2D/prediabetes
  • Classification
  • Diagnostic tests
  • Prediabetes
  • Comprehensive evaluation & assessment of comorbidities

Pharmacologic Approaches
Lauren C. Vincent, MD; Athena Philis-Tsimikas, MD

  • Goals of therapy/glycemic targets
  • Overview of efficacy and safety of different classes
  • Overview of guidelines
  • Stepwise approach to therapy
  • Therapy according to comorbidities/ risk factors (HF, ASCVD, CKD)

Intensive/Advanced Glycemic Management
Irl B. Hirsch, MD; Anne L. Peters, MD

  • Continuous Glucose Monitoring (CGM): Rationale & Overview
  • Pumps, Insulin Delivery Systems, and Connected Insulin Pens
  • Injectable Therapies for Diabetes (Insulin and Non-Insulin Injectables)

Target Audience

The Foundations of Cardiometabolic Health Certification Course is appropriate for clinicians from a full spectrum of clinical experience including Physicians, Physician Assistants, Nurse Practitioners, Registered Nurses, Pharmacists, Diabetologists, and Dietitians who are in any phase of training, or even experienced physicians who are looking to take a deeper dive into cardiometabolic health.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify risk factors, as well as screening and diagnostic criteria in order to identify patients with type 2 diabetes or prediabetes in a timely manner.
  • Discuss efficacy and safety of medication classes for type 2 diabetes.
  • Review current guidelines and evidence-base for the individualization of T2DM therapy.
  • List the efficacy and safety of approaches for intensive glycemic management in patients with type 2 diabetes, including continuous glucose monitoring, insulins, and insulin delivery systems.
  • Select evidence-based therapy for patients with type 2 diabetes and comorbidities such as ASCVD, HF, or CKD.

Additional Information

Course summary
Available credit: 
  • 6.00 ABIM MOC and AMA PRA Category 1 Credit
  • 6.00 ACPE Pharmacy
  • 6.00 AMA PRA Category 1 Credit
  • 6.00 ANCC
  • 6.00 CDE
  • 6.00 Participation
Course opens: 
02/21/2022
Course expires: 
06/24/2023
Rating: 
0

Kathleen Dungan, MD, MPH
Division of Endocrinology, Diabetes & Metabolism
The Ohio State University

Dr. Dungan discloses the following:
Consultant: Eli Lilly, Tolerion, Boehringer Ingelheim, Janssen, Novo Nordisk
Research Support: Sanofi Aventis, Novo Nordisk, Viacyte, Abbott, Dexcom

Lauren Vincent, MD
Division of Diabetes & Endocrinology, SCMG
Scripps Whittier Diabetes Institute

Dr. Vincent has no relevant financial relationships to disclose.

Athena Philis-Tsimikas, MD
Division of Diabetes & Endocrinology, SCMG
Scripps Whittier Diabetes Institute

Dr. Philis-Tsimikas has no relevant financial relationships to disclose.

Irl B. Hirsch, MD
University of Washington School of Medicine
Seattle, WA

Dr. Hirsch discloses the following:
Consultant: Abbott Diabetes Care, Bigfoot, Roche, GWave
Research Support: Medtronic Diabetes, Insulet, Beta Bionics

Anne Peters, MD
Director, USC Clinical Diabetes Programs
Professor of Medicine (Clinical Scholar)
USC Keck School of Medicine
Los Angeles, LA

Dr. Peters discloses the following:
Advisory Board: Abbott Diabetes Care, Lilly, Novo Nordisk, Vertex, Zealand
Research Support: Dexcom, Insulet, Abbott
Stock Options: Omada Health, Livongo/Teladoc

ESTIMATED TIME TO COMPLETE ACTIVITY
6 hours

JOINT ACCREDITATION STATEMENT
    image

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
Partners for Advancing Clinical Education designates this enduring material for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 6 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Partners for Advancing Clinical Education designates this continuing education activity for 6 contact hour(s) (0.6 CEUs) of the Accreditation Council for Pharmacy Education.

This is an application-based activity. Universal Activity Numbers (UAN): JA4008073-9999-22-003-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

CONTINUING DIETICIAN EDUCATION
This program offers 6 CPEUs for dieticians.

ABIM MOC CERTIFICATION

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6 MOC points in the American Board of Internal Medicine's (ABIM) maintenance of certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MERIT-BASED INCENTIVE PAYMENT PROGRAM (MIPS)

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).

DISCLOSURE OF CONFLICTS OF INTEREST
Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PACE planners and others have nothing to disclose. The CMHC planners and others have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT
During the period February 21, 2022 through June 24, 2023, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at Foundations@cardiometabolichealth.org.


For questions about the accreditation of this activity, please visit www.clinicaleducationalliance.com.

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

For MIPS:
1) Complete this module post-test and evaluation.
2) Over the next 90 days, actively work to incorporate improvements in your clinical practice from these presentations.
3) Complete the follow-up survey from CMHC in approximately 90 days.

Available Credit

  • 6.00 ABIM MOC and AMA PRA Category 1 Credit
  • 6.00 ACPE Pharmacy
  • 6.00 AMA PRA Category 1 Credit
  • 6.00 ANCC
  • 6.00 CDE
  • 6.00 Participation
 
Status
Price
Title
$0.00Included
Please login or register to take this course.
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.